Funder: Gilead Sciences
Due Dates: January 30, 2026 (LOI – HIV Prevention: INCLUSION Global 2026) | April 3, 2026 (Full – HIV Prevention: INCLUSION Global 2026) | May 4, 2026 (LOI – HIV: RESONATE 2026) | May 29, 2026 (Full – HIV: RESONATE 2026) | June 30, 2026 (LOI – AmBisome)
Funding Amounts: Up to $5,000,000 (INCLUSION Global 2026) | Up to $4,000,000 (RESONATE 2026) | Typical project duration: 18–24 months | Overhead max: 30%
Summary: Supports high-impact research projects in HIV prevention and management, invasive fungal infections, and hepatitis B, C, and D to advance clinical practice and patient outcomes in virology and infectious diseases.
Key Information: LOIs required for most programs; only specific countries eligible for some RFPs; applications via Gilead OPTICS portal.